Expert Point of View: Oncotype DX

Get Permission

“Prostate cancer is a heterogeneous disease and has not yet benefitted from personalized medicine discoveries. Anything that gets us closer to personalized medicine [for prostate cancer] is a plus,” said Michael J. Morris, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, New York, when asked about the Oncotype DX prostate cancer assay. “To decide which patients are appropriate for active surveillance on a molecular basis would be great. It is fabulous to have a foothold in personalized medicine,” he added.

Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Las Vegas, said that he has already begun to use the Oncotype DX assay in his practice. “It has great promise. I see a lot of men with Gleason 6 scores who don’t want surgery, yet they have a tremendous amount of anxiety. This test could reassure those patients. The biggest issue from my perspective is insurance coverage,” Dr. Vogelzang commented.

“This test is a great example of precision medicine. You would like to know which group of men with Gleason 6 scores should not be managed by active surveillance,” Dr. Vogelzang stated. ■

Disclosure: Drs. Morris and Vogelzang reported no potential conflicts of interest.

Related Articles

Two New Genetic Tests Offer Progress in Personalized Medicine for Newly Diagnosed Prostate Cancer

At least 12 different genetic tests for prostate cancer are under development. The two tests currently available are Oncotype DX (Genomic Health, Redwood City, California) and Prolaris (Myriad Genetic Laboratories, Salt Lake City). Both tests can identify which low-risk patients are “truly” at low...

Expert Point of View: Prolaris

Scott Tomlins, MD, PhD, a pathologist at the University of Michigan, Ann Arbor, was cautiously optimistic about this new test. “Whenever you introduce a new biomarker, you need to demonstrate its ability to impact clinical decision-making, and it needs to improve on what we currently have,” he...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.